Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 1,000
- Avg volume
- 4,872
- Day's range
- $0.60 – $0.60
- Shares out
- —
- Stochastic %K
- 3%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and M...
Show more
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive assays mimicking the genetic disease state, enabling discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a custom-built, cloud-distributed analytics platform that captures data for AlloChem compounds in CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 412 206 5303
- Website
- https://sharptx.com
- Address
- 2403 Sidney Street, Suite 264, Pittsburgh, United States
Latest news
No headlines yet.
